Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03029325

Molecular and Genetic Analysis of Lung Cancer

Investigators use a genome-wide approach within a case-control design to identify SNPs that show evidence of association with lung cancer risk and survival.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Lung Cancer Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location status: Recruiting

Location contact

Andrea Shafer, MPH

CONTACT

6177269274

About this study

Investigators also investigate how genetic variants may affect cancer treatment, at various stages of disease development, in order to determine prognostic and predictive factors for survival.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • healthy controls: participants without evidence of any cancer
  • cases: pathology proven primary lung cancer

Exclusion criteria

  • younger than 18 years old

Treatment and study plan

Primary outcomes

  1. Survival among patients at different stages of lung cancer and treatment will be measured using questionnaires along with medical chart data to monitor treatment and disease progression

    Time frame: 20 years

    Study lung cancer development in a case control study. We will look at three separate outcome measures specified below

Secondary outcomes

  1. Overall survival

    Time frame: 20 years

    Measurement from time of diagnosis to death will be obtained

  2. Progression-free survival

    Time frame: 20 years

    Time of diagnosis to disease progression (measured by metastasis)

  3. Treatment toxicities

    Time frame: 20 years

    Effects on ECOG and physical sequelae from treatment (radiation, chemotherapy and other treatment modalities will be analyzed)

Study contacts

Contact information is provided by the study sponsor or research team.

Andrea Shafer, MPH

CONTACT

[email protected]

6177269274

David Christiani, MD

CONTACT

[email protected]

617-726-9274

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Important dates

Study start
1993
Primary completion
2026
Study completion
2026
First posted
Jan 24, 2017
Registry last updated
Nov 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.